Humanin vs PT-141 (Bremelanotide)
Updated July 28, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Humanin and PT-141 (Bremelanotide) (also searched as PT-141 (Bremelanotide) vs Humanin) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Humanin centers on healing, while PT-141 (Bremelanotide) leans toward neuro. On indexed research, Humanin is ahead (Humanin: 13 studies, Human evidence; PT-141 (Bremelanotide): 13, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Humanin is strongest for healing; PT-141 (Bremelanotide) for neuro.
- •Evidence: Humanin Human evidence (13 studies) vs PT-141 (Bremelanotide) Human evidence (13).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
Mitochondria-Derived Peptide | HN
Melanocortin agonist | Sexual dysfunction
Humanin vs PT-141 (Bremelanotide): side-by-side
| Metric | Humanin | PT-141 (Bremelanotide) |
|---|---|---|
| Class | Longevity | Healing |
| Regulatory status | Research use only | FDA-approved |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 13 | 13 |
| Research level | Moderate Research | FDA Approved |
| Strongest effect | Healing & recovery | Neuro & mood |
| Healing & recovery | 4.0▲ | 0.0 |
| Muscle & body comp | 1.0▲ | 0.0 |
| Metabolic & appetite | 4.0▲ | 0.0 |
| Neuro & mood | 3.0▲ | 3.0▲ |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 3.0▲ | 1.0 |
| Skin & aesthetics | 0.0 | 0.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Humanin | PT-141 (Bremelanotide) |
|---|---|---|
| Mechanism | — | Melanocortin receptor agonist |
| Route | — | Subcutaneous injection |
| Half-life | — | ~2.7 hours |
| Time to peak | — | 1 hour |
| Duration of action | — | Up to 24 hours |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Humanin?
Mitochondria-associated peptide explored for longevity, metabolic, and organ-protective effects.
Full Humanin profile, mechanism & studies →What is PT-141 (Bremelanotide)?
### Summary PT-141 (Bremelanotide) is a synthetic peptide that acts as a melanocortin receptor agonist, primarily investigated for its potential to treat sexual dysfunction, particularly in women experiencing hypoactive sexual desire disorder. Its mechanism of action involves the modulation of pathways related to sexual arousal and desire.
Full PT-141 (Bremelanotide) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Humanin | 4.0/5 effect signal |
| Muscle | Humanin | 1.0/5 effect signal |
| Metabolic | Humanin | 4.0/5 effect signal |
| Neuro | Even | Both ~3.0/5 |
| Inflammation | Humanin | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Humanin and PT-141 (Bremelanotide)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Humanin vs PT-141 (Bremelanotide): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Humanin has 13 approved studies indexed (Human evidence), and PT-141 (Bremelanotide) has 13 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Humanin or PT-141 (Bremelanotide) better?
It depends on your goal. Humanin is strongest for healing; PT-141 (Bremelanotide) for neuro. Humanin has more indexed studies (13). See the goal-by-goal breakdown above.
Is Humanin or PT-141 (Bremelanotide) better for weight loss?
Humanin shows the stronger metabolic & appetite profile (4.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Humanin or PT-141 (Bremelanotide) better for muscle?
Humanin leads on the muscle & body-composition axis (1.0/5).
Which has more research, Humanin or PT-141 (Bremelanotide)?
Humanin has 13 approved studies indexed (Human evidence); PT-141 (Bremelanotide) has 13 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Humanin and PT-141 (Bremelanotide)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Humanin vs PT-141 (Bremelanotide)?
Humanin: no community-reported effects logged yet. PT-141 (Bremelanotide): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Humanin or PT-141 (Bremelanotide) FDA-approved?
Humanin is a research-use compound and is not FDA-approved. PT-141 (Bremelanotide) is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is PT-141 (Bremelanotide) better than Humanin?
For neuro, PT-141 (Bremelanotide) has the edge; for healing, Humanin does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 28, 2026.